Latest Intelligence on Pharmaceuticals and Healthcare in Norway

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

AstraZeneca: Crestor experiences additional setbacks

Withdrawal from the European approval process by three member states represents additional obstacles for Crestor, heightens concerns over safety, and will undoubtedly slow revenue gains for AstraZeneca. Therefore, although forecast to achieve blockbuster sales of $3.8 billion in 2010, Crestor will fail to make as significant an impact on the anti-dyslipidemic market as Lipitor did upon launch.

Published By Datamonitor
12 Mar 2003
CommentWire
CommentWire

Algeta: Alpharadin clears hurdle but more to come

Algeta has announced that Apharadin met its primary endpoint in a bone marker analysis in a phase II hormone-refractory prostate cancer trial, demonstrating its potential in bone metastases. However, this must be translated into survival and/or quality-of-life advantage to guarantee a successful launch. Algeta must also find a suitable marketing partner to bring the product to the market.

Published By Datamonitor
27 Feb 2006

« | 1 | » »|

No help is available.